[RagingBull All-Access]
Dear trader,
Tonight at 7 pm, just a few hours from now, [Jason Bond’s next Master Class session]( begins.
During this session, he’s going to reveal his [best instrument for trading.](
With a busy week ahead on the economic and earnings front, you don’t want to miss this!
All these catalysts make it difficult to separate the wheat from the chaff when it comes to finding great setups.
But Jason has your back.
It only costs five bucks to enroll in his 12-week course—you’ll also get a one-month subscription of Jason’s Jackpot Trades service totally free of charge.
That’s right… FOUR of Jason’s highest conviction trade ideas — absolutely free, but only if act on this now.
Just one of his trades has the potential to change the trajectory of your financial future.
[We’ll see you at Master Class here in just a few hours.](
[Image](
[I'm an image]
[Jump on the Week – FXI, TSLA, QQQ](
By Jeff Bishop of Total Alpha
[Image](
The S&P staged a major comeback last week, totally erasing the coronavirus losses from the week before.
Notable movers included technology companies and the QQQ — as well as Tesla, which [one Total Alpha subscriber scored a whopping 2,800% gain]( on in just two days.
In this post, Jeff Bishop takes a look at robust data driving the economy, the coronavirus supply chain impact, and the contested Iowa results.
He’ll also reveal what stocks he’s currently watching and what’s on the corporate and economic calendar this week.
[Continue reading...](
[You can join the Total Alpha mailing here.](
[Casper’s Mattress IPO Price Tag… A Bargain?](
By Ben Sturgill of IPO Payday
[Image](
The highly anticipated Casper IPO went LIVE on Thursday under the ticker symbol CSPR, and it may be listed at a bargain price.
While the company initially aimed to offer its stock between $17 and $19 per share, they slashed their initial projections to between just $12 and $13.
The company is now valued at $520 million, down from an earlier $760 million — and down even further from an initial $1.1 billion that once gave the company a coveted “unicorn” status.
In this post, Ben Sturgill explores whether the recent Casper price drops give it his green light buy signal… or whether all the recent pessimism around its debut means it’s preparing for an even bigger meltdown.
[Continue reading...](
[You can join the IPO Payday mailing here.](
[3 Trades To Woo Your Lover on Valentine’s Day](
By Nathan Bear of Weekly Money Multiplier
[Image](
Every once in a while, Nathan Bear falls in love with a stock. And he plays it over and over… and over.
Roku was a perfect recent example of that. But this Valentine’s day week, Nate has his heart set on a few other stocks.
This first one is Zoom (ZM), the recent video communication IPO that caught a nice bounce last week after people downloaded the platform in mass following the coronavirus outbreak.
Learn about his other two favorites in today’s post.
[Continue reading...](
[You can join the Weekly Money Multiplier mailing here.](
[Wall Street Scandal: Clovis Oncology’s (CLVS) $298M Theft](
By Kyle Dennis of Biotech Breakouts
[Image](
Ever since Kyle Dennis started his Dollar Ace trading service, he’s been on the lookout for unusual options activity made by Wall Street’s dirtiest players.
Unusual options activity means there's usually some kind of insider activity involved… like someone knows something.
In this issue of American Greed, Kyle shares a story about a publicly-traded pharmaceutical company (Clovis Oncology) and how it raised $298M by lying to everyday investors and traders.
He’ll explain how he’s taking profits by identifying situations like this every day.
[Continue reading...](
[You can join the free Biotech Breakouts mailing here.](
To your success,
The RagingBull.com Team
[Stop receiving exclusive emails from RagingBull All Access](
Neither RagingBull nor RagingBull.com, LLC (publisher of RagingBull) is registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for RagingBull.com, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are actual figures from the portfolios RagingBull manages on behalf of RagingBull.com, LLC.
[Unsubscribe from all RagingBull Emails](